Opinion|Videos|November 19, 2026

HER2 Expression Levels, Carcinosarcoma, and Tumor Heterogeneity

Bradley R. Corr, MD, of University of Colorado Cancer Center, and Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, explain how HER2 expression level affects their use of trastuzumab deruxtecan in endometrial cancer, with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center.

Bradley R. Corr, MD, of University of Colorado Cancer Center, and Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, explain how HER2 expression level affects their use of trastuzumab deruxtecan in endometrial cancer, with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center. Corr describes himself as cautiously optimistic, calls the DESTINY data very promising, and says a 3+ score drives him toward the agent while a 2+ score makes him more hesitant. Secord agrees, noting a response rate over 80% in the 3+ group and about 60% in the 2+ group despite a small 40-patient cohort, and says further refinement is needed to identify who benefits most. Westin notes the agent has a compendium listing and her group has started using it for carcinosarcoma. The panel also discusses whether to rebiopsy at recurrence, concerns about tumor heterogeneity, and the bystander effect.

Bradley R. Corr, MD, of University of Colorado Cancer Center, and Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, explain how HER2 expression level affects their use of trastuzumab deruxtecan in endometrial cancer, with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center. Corr describes himself as cautiously optimistic, calls the DESTINY data very promising, and says a 3+ score drives him toward the agent while a 2+ score makes him more hesitant. Secord agrees, noting a response rate over 80% in the 3+ group and about 60% in the 2+ group despite a small 40-patient cohort, and says further refinement is needed to identify who benefits most. Westin notes the agent has a compendium listing and her group has started using it for carcinosarcoma. The panel also discusses whether to rebiopsy at recurrence, concerns about tumor heterogeneity, and the bystander effect.


Related to this article